“We don’t really have anything to talk about right now, so we’re not going to discuss adverse events
or discontinuation rates, but everything is consistent with what we thought it would be, so far,” said Renz, calling the drug well tolerated, with no severe adverse events"
We do believe that we’re sitting on a potential blockbuster,” Renz said, especially if Z160 can get the job
done without side effects, which can be nasty with pain drugs. “The cover-up is worse than the crime, sometimes,” he said. “The goal is to keep going [with trials] as far as we can, but we expect solicitation from all the major pain players and the major specialty pharmaceutical companies
that focus on pain,” he said. “They’re all aware of our program, and they’ve all asked us to call them ﬁ rst when the data come in. We believe a partnership will be the ultimate outcome.”